Breaking News

Lilly Pauses ACTIV-3 Clinical Trial in Hospitalized COVID-19 Patients

ACTIV-3 study is evaluating the efficacy of Lilly’s neutralizing antibody in hospitalized COVID-19 patients, the most advanced stage of the disease.

By: Contract Pharma

Contract Pharma Staff

Lilly has paused enrollment in its ACTIV-3 study evaluating the antiviral drug Remdesivir plus an experimental antibody therapy being developed by Lilly in patients hospitalized with COVID-19. According to the company, independent monitors paused the study out of an abundance of caution. Study pauses are not uncommon in clinical trials and are often resolved. The trial began in August and aims to enroll 10,000 hospitalized COVID-19 patients in the U.S., Denmark and Singapore. Trial partici...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters